Geron: 3 Key Takeaways for Long-Term Investors
· fool.com · popularity 13/100 · 0 similar stories today · Breaking & World News (World News & Media)
Read the original at fool.com →
Summary
Operating expenses fell 9% year to date, and $339 million in cash leaves Geron room to pursue hematology deals. On its third quarter of 2026 earnings …
Found in: The Motley Fool. Rating basis: single outlet; outlet tier 2 (unlisted); 1 feeds; feed position 28.